Phathom Pharmaceuticals, Inc. Common Stock PHAT
i
Market dataready · fetched 2026-11-12T02:41:02.396Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:21:28.371101714Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T02:41:01.896733+00:00
Phathom Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.03 | 486.4% | 158.6% | 4.83 | 800.0% | 62.5% |
| 25Δ | 14.91 | 515.7% | 143.8% | |||
| 30Δ | 14.48 | 566.6% | 142.3% | |||
| 35Δ | 14.05 | 617.5% | 140.8% | |||
| 40Δ | 13.62 | 668.5% | 139.3% | |||
| 45Δ | 13.18 | 719.4% | 137.8% | |||
| 50Δ | 12.75 | 770.3% | 136.3% | |||
| 55Δ | 11.81 | 772.0% | 124.6% | |||
| 60Δ | 10.17 | 705.1% | 98.7% | 7.97 | 284.7% | 10.0% |
| 65Δ | 8.52 | 638.2% | 72.8% | 8.63 | 294.2% | 8.5% |
| 70Δ | 6.87 | 571.3% | 46.8% | 9.29 | 303.7% | 7.1% |
| 75Δ | 5.23 | 504.4% | 20.9% | 9.94 | 313.2% | 5.6% |
| 80Δ | 14.52 | 446.7% | 5.5% | |||
20Δ
- Pseudo strike
- 16.03
- IV
- 486.4%
- B/E move
- 158.6%
- Pseudo strike
- 4.83
- IV
- 800.0%
- B/E move
- 62.5%
25Δ
- Pseudo strike
- 14.91
- IV
- 515.7%
- B/E move
- 143.8%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 14.48
- IV
- 566.6%
- B/E move
- 142.3%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 14.05
- IV
- 617.5%
- B/E move
- 140.8%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 13.62
- IV
- 668.5%
- B/E move
- 139.3%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 13.18
- IV
- 719.4%
- B/E move
- 137.8%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 12.75
- IV
- 770.3%
- B/E move
- 136.3%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 11.81
- IV
- 772.0%
- B/E move
- 124.6%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 10.17
- IV
- 705.1%
- B/E move
- 98.7%
- Pseudo strike
- 7.97
- IV
- 284.7%
- B/E move
- 10.0%
65Δ
- Pseudo strike
- 8.52
- IV
- 638.2%
- B/E move
- 72.8%
- Pseudo strike
- 8.63
- IV
- 294.2%
- B/E move
- 8.5%
70Δ
- Pseudo strike
- 6.87
- IV
- 571.3%
- B/E move
- 46.8%
- Pseudo strike
- 9.29
- IV
- 303.7%
- B/E move
- 7.1%
75Δ
- Pseudo strike
- 5.23
- IV
- 504.4%
- B/E move
- 20.9%
- Pseudo strike
- 9.94
- IV
- 313.2%
- B/E move
- 5.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.52
- IV
- 446.7%
- B/E move
- 5.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 192.34% | |
| 182.33% | |
| 186.30% | |
| 182.53% | |
| 236.32% | |
| 242.91% |
Biotechnology
PHVS
Description unavailable
More →PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary…
More →PRAX
Description unavailable
More →PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
More →